{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Blad1"],"not_rendered":{"external_links":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Blad1","index":0,"n_rows":11,"n_cols":2,"rows_kept":11,"merged":[[0,0,0,1],[10,0,10,1]],"flags":["formulas_cached_only"]}
["Table 2 Exclusion criteria"]
["1.","Patients who are pregnant or nursing and those who plan pregnancy in the period up to 1 months after the study."]
["2. ","Women of childbearing potential not using contraception."]
["3.","Patients with a limited life expectancy less than 1 year."]
["4.","Contra-indication for macitentan:"]
[null,"- Patients with active liver disease or severe liver dysfunction with ASAT and/or ALAT >3x upper limit of normal (ULN)."]
[null,"- Patients with known renal impairment (GFR <60 ml/min)."]
[null,"- Patients with anemia."]
[null,"- Use of potent CYP3A4 inducers (rifampicin, St. John's wort, carbamazepine, phenytoin) due to reduced efficacy of macitentan."]
[null,"- Use of potent CYP3A4 inhibitors (itraconazole, ketoconazole, voriconazole, clarithromycin, ritonavir, saquinavir)."]
["ASAT aspartate aminotransferase, ALAT alanine transaminase, eGFR estimated glomular filtration rate, CYP3A4 Cytochrome P450 Family 3 Subfamily A Member 4"]